Financials data is unavailable for this security.
View more
Year on year Fuji Pharma Co Ltd grew revenues 15.42% from 35.43bn to 40.89bn while net income improved 27.40% from 2.70bn to 3.44bn.
| Gross margin | 39.28% |
|---|---|
| Net profit margin | 14.28% |
| Operating margin | 11.75% |
| Return on assets | 7.36% |
|---|---|
| Return on equity | 14.90% |
| Return on investment | 11.63% |
More ▼
Cash flow in JPYView more
In 2023, cash reserves at Fuji Pharma Co Ltd fell by 1.22bn. However, the company earned 1.92bn from its operations for a Cash Flow Margin of 4.69%. In addition the company generated 1.92bn cash from financing while 5.24bn was spent on investing.
| Cash flow per share | 405.15 |
|---|---|
| Price/Cash flow per share | 3.25 |
| Book value per share | 1,849.15 |
|---|---|
| Tangible book value per share | 1,415.66 |
More ▼
Balance sheet in JPYView more
| Current ratio | 1.21 |
|---|---|
| Quick ratio | 0.6276 |
| Total debt/total equity | 0.6426 |
|---|---|
| Total debt/total capital | 0.3912 |
More ▼
Growth rates in JPY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 5.71% and 27.37%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.68% |
|---|---|
| Div growth rate (5 year) | 5.73% |
| Payout ratio (TTM) | 15.28% |
| EPS growth(5 years) | 4.64 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 212.43 |
More ▼
